Adverts

Open Access Articles- Top Results for Radequinil

Radequinil

</th></tr>
Radequinil
File:Radequinil.svg
Systematic (IUPAC) name
5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
Clinical data
Identifiers
219846-31-8
None
PubChem CID 22714308
ChemSpider 11584471
Chemical data
Formula C18H14N4O3
334.329 g/mol

Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor.[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.[1][2]

See also

References

  1. ^ a b Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer’s Disease" (PDF). The Open Neuropsychopharmacology Journal 1: 19–23. 
  2. ^ Pogacic, Vanda; Herling, Paul (2007). "List of Drugs in Development for Neurodegenerative Diseases". Neurodegenerative Diseases 4 (6): 443486. ISSN 1660-2862. doi:10.1159/000107705. 


Lua error in package.lua at line 80: module 'Module:Buffer' not found.